Venture PartnerBright Capital
Based in New York, Mr. Austin has been a Venture Partner with Bright Capital since 2012, where he focuses broadly on alternative energy, resource and energy efficiency, distributed generation, water, advanced materials and cleantech, providing leadership and strategic guidance for Bright Capital's investment strategy and portfolio companies, including serving on the Boards of Agrivida, QM Power and Ener-G-Rotors.
Prior to Bright Capital, as Managing Director of Chandler Reed LLC, Mr. Austin served as a strategic advisor to CEOs of public and private growth stage companies, new ventures and tech start-ups, and was a consultant at UNDP's Sustainable Energy & Environment Division in the area of sustainable technologies globally, as well as to other UN agencies. He has applied his knowledge of finance and marketing, intellectual property, technology commercialization and strategy across a broad and diverse range of industries. Earlier, Mr. Austin has been a serial tech entrepreneur in the fields of electro-optics, medical devices, and materials manufacturing systems. As a start-up entrepreneur, he has patents issued in 30 countries and has won international design awards.
Mr. Austin is an advisor to tech start-up incubators and accelerators, and is an Entrepreneur-in-Residence (EIR) with NYSERDA and the SUNY College of Nanoscale Science and Engineering, as well as serving on the National Renewable Energy Lab's (NREL) Investment Advisory Board. Mr. Austin has mentored entrepreneurs in different regions of Africa, and spoken at conferences from Krasnoyarsk to Kingston, from Beijing to Bilbao, on venture investing, entrepreneurship, strategy, innovation and sustainable technologies.
Mark Austin is a graduate of Williams College.
Christina Bechhold Russ
InvestorSamsung NEXT Ventures
Christina Bechhold Russ is an Investor at Samsung NEXT Ventures, based in New York, focused on early stage investments in software and services, particularly in mobility, consumer IoT and fintech.
She is also Co-Founder and Managing Director of Empire Angels, a member led angel group of young professionals investing in technology startups with a focus on supporting young entrepreneurs.
Christina is a Regular Contributor for the Wall Street Journal on startups and small business, a columnist for Inc.com, a mentor at The Brandery and Venture for America and a member of VFA's Rise Committee focused on increasing diversity in entrepreneurship. She is a frequent speaker and panelist at events in the U.S., Europe and Asia, a TEDx speaker, and was recognized by the New York Business Journal as a 2016 Woman of Influence.
PartnerPartners Healthcare Innovation Fund
Carl's career has spanned over 25 years in the practice and management of innovation to bring new technologies from lab to market.
As a bench scientist and R&D director, he worked at Polaroid Corporation and Hygeia Sciences in the development of photographic and clinical products for both consumer and professional markets. He is an inventor on 6 US patents. He served as a Partner at Integral/Analysis Group, a consulting firm focusing on the management of innovation and growth strategy for clients in healthcare and consumer products. He has been an active private equity investor as a member of Angel Healthcare Investors LLC and is a founder of Mass Medical Angels. He has served on the boards of Quosa [research literature management software], Kasalis [robotics], Combinent [women's health], Infobionic [cardiac monitoring], Annovation [anesthetic agent] and currently sits on the board of Syntimmune [immunotherapy], QPID Health [bioinformatics], LifeImage [diagnostic image sharing], Sebacia [dermatology therapy] and the Sudanese Education Fund [philanthropy].
Carl holds an AB degree from Cornell University and received his PhD in Organic Chemistry from the University of California at Berkeley. He also holds an appointment as Lecturer in the MIT Sloan School of Management teaching various courses on the topic of biomedical enterprise.
Maria Berkman, MD, shares responsibility for the day-to-day operations of Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement.
Prior to joining Broadview Ventures Maria was a management consultant at Monitor Group (now Monitor Deloitte), where she specialized in life sciences with a focus corporate strategy, franchise and asset-level commercialization strategy, and competitive strategic planning for a broad range of biopharma clients. Before joining Monitor Group, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital, with a focus on General Surgery. Maria earned her MD from the UCLA School of Medicine, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery. Maria earned her MBA from the Anderson School of Management at UCLA.
Maria currently serves as the Board Observer for 480 Biomedical, Apama, BioKier, Cardero, Cardialen, Vascular Graft Solutions and Zumbro Discovery and is a Board Director of FineHeart.
In addition to her role at Broadview Ventures, Maria contributes time as a grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD Biomed Accelerator in Tel Aviv, Israel.
FounderRed Sea Ventures
Scott is the founder of Red Sea Ventures. He combines 15 years of entrepreneurial experience including his time as co-founder of Epok, an early cloud-based enterprise solution launched in 2001. He has experience as a corporate attorney at White & Case and digital media expertise developed at CBS local where he focused on strategy and business development.
Scott is a member of the board of Seeds of Peace, a founding member of Young Leadership Committee (YLC) and served as chairman of the YLC board. Scott is the recipient of the Young Peace Maker award for his outstanding leadership in and dedication to supporting the mission of seeds of peace and the YLC.
Scott grew up in Paris and attended Georgetown University and Fordham Law School.
Venture PartnerNextGen Venture Partners
Vaughn Blake is the Founder and Managing Director of Autochrome Ventures and Autochrome Capital Management.
Additionally, he is a venture partner at NextGen Venture Partners.
Prior to managing Autochrome, Vaughn spent time as an operator, investor, algorithmic trader and founder.
Vaughn is a graduate of Colorado College.
InvestorEcosystem Integrity Fund
Sasha Brown is an Investor at the Ecosystem Integrity Fund. Her responsibilities include investment due diligence, strategy development, deal sourcing, and portfolio company support. She assists with system and sector analysis, firm operations, and financial structuring.
Prior to joining EIF, Sasha was a Principal at NewWorld Capital Group, where she co-led investments including SolarEdge Technologies, which had a successful IPO in 2015, and Astrum Solar, which was sold to Direct Energy.
Sasha serves as Board Director at PosiGen Solar Solutions and a Board Observer at Opti RTC. She received a BS in Environmental Engineering from Yale University and an MBA from the Yale School of Management.
Managing DirectorEnergy Foundry
Sara leads venture investment activity for Energy Foundry, an early-stage venture fund based in Chicago. She maintains an active role with each of the firm's portfolio companies, and sits on the Board of SiNode Systems, Advanced Diamond Technologies and Tank Utility.
Prior to Energy Foundry, Sara built a government advisory practice at Wilson Sonsini Goodrich & Rosati and helped energy startups raise $300M in non-dilutive funding. She has also held roles with GE Energy and environmental consulting firm, GaiaTech.
Sara holds an MBA from the University of Chicago Booth School of Business, and an undergraduate degree from Emory University. In 2015, she was recognized by Midwest Energy News ''40 Under 40.''
Managing DirectorCorrelation Ventures
David began his venture capital career in 1997.
Prior to founding Correlation Ventures, David was a Managing Director of Hamilton BioVentures, an early-stage venture capital fund based in San Diego. As head of Hamilton's Life Science team, David served on the Board of Directors of such companies as PhotoThera, Transcept (NASDAQ: TSPT), and Egea Biopharmaceuticals (Acquired by Johnson&Johnson).
Previously, David was a Venture Partner at Windamere Venture Partners and President of Forge Medical Ventures, an early-stage incubator funded by Enterprise Partners, Mayfield Fund and Johnson & Johnson Development Corporation. David was the Founder of Spine Wave, a venture-funded medical device company and Director of Business Development of UroMed Corporation (URMD), a venture-funded startup that raised several rounds of venture capital and completed a public offering.
David received an M.B.A. from the Harvard Graduate School of Business Administration and graduated Summa Cum Laude with a B.S. in Biology from Princeton University.
Investment PartnerBP Ventures
Miriam Eaves, Venture Partner, BP Ventures which invests in businesses that support BP's core business and build a low carbon economy, including mobility. She is focused on identifying US investment opportunities in the Mobility/Transportation sector Smart Mobility. Specifically: Mobility as a Service, Intelligent Operations, Power & Storage, Bio and Low Carbon and Carbon Management.
She is the Founder and MD of the Cargile Group, a corporate development Advisory firm. Ms. Eaves is a Board Member of the WPA, a service and advocacy group for women.
She holds a BA in Environmental Studies from the University of North Carolina and an MBA from the University of Virginia.
Managing DirectorGlasswing Ventures
Sarah Fay is Managing Director at Glasswing Ventures, an early-stage venture capital firm dedicated to building the next generation of AI technology companies that address the connected world and the security of the ecosystem.
Sarah has more than 20 years of experience in the marketing services industry, with a track record of leveraging technology to deliver groundbreaking new models for advertising and media. In her role at Glasswing Ventures, Sarah leads and evaluates investments in early stage AI-powered companies. Her prior investments include X+1, Namely, Mogul, Mavrck, Evidon, Tick/r, TVision Insights and Humon.
Sarah has served as Independent Director on the Boards of public and private technology and digital media companies such as Celtra, SocialFlow, The Street (Nasdaq:TST), Women's Marketing, Inc. (acquired by Stephens Inc.), and [X+1] (acquired by Rocket Fuel). She served as CEO of Aegis Media North America, a media and digital marketing communications company, where she was also responsible for launching and growing a significant part of that business during her eleven-year tenure. Previously, Sarah served as President of Carat US, and Isobar US, where she was tasked with the integration of digital and traditional media services.
Sarah's contributions to the broader community include serving on the Executive Board of the Ad Club of Boston, as Director on the Board of The Massachusetts Innovation and Technology Exchange (MITX) and as Board Advisor to Advertiser Perceptions. She is a Board Advisor to Adelphic Mobile, clypd, Colspace and Viral Gains.
Sarah earned a BA in English from the University of Vermont and has received over 30 accolades and awards for her accomplishments such as "Media All Star" (AdWeek), "Top 100 Most Influential People in Media (MediaPost) and "Fast 50" (Fast Company).
Managing DirectorMPM Capital
Bard Geesaman, M.D., Ph.D., has been affiliated with MPM and associated portfolio companies since 2002. With broad experience investing, operating and facilitating business development globally, including in Japan, China and Israel, Bard is a Managing Director of MPM's Oncology Impact Fund (OIF) and serves as Chief Compliance Officer (CCO).
Prior to MPM, Bard founded Catalyst Medical Solutions, a medical documentation and billing eHealth company in Boston where he served as the Chief Technology Officer through the company's acquisition. After Catalyst, Bard joined Centagenetix, an MPM-founded company exploring the genetics of successful aging.
In 2006, Bard joined MPM as a Venture Partner with a major focus on founding Solasia Pharmaceuticals, based in Tokyo, Japan. Bard is also the co-founder and a board member of MPM healthcare IT startup TriNetX (big data analytics for clinical trials). Bard is passionate about innovation in health care, and in 2008 took a two year sabbatical from MPM to do non-profit work in Los Angeles at the X-Prize Foundation, where he worked on alternative models for motivating life sciences innovation.
He received a BS in neuroscience from UC Berkeley followed by concurrent degrees from Harvard Medical School and the Massachusetts Institute of Technology, with his PhD work focused on systems and computational neurobiology. Bard finished his medical training by completing a three-year medical residency at Massachusetts General Hospital.
Managing DirectorBoehringer Ingelheim Venture Fund
Martin joined the Boehringer Ingelheim Venture Fund in 2010 to invest in early innovative therapeutic life science companies. In October 2013, Martin established the US-office of BIVF in Cambridge, MA, where he is focusing on biotech seed-investments. He has 15 years of investing and commercial experience in both venture capital and global pharma companies. He serves as board member of AMP Therapeutics in Leipzig, ArmaGen in Calabasas, 121bio in Cambridge and Sentien in Medford.
Prior to BIVF, Martin held several global roles in Marketing at Boehringer Ingelheim and Solvay Pharmaceuticals and was involved in the global launch of several products in the area of CNS. Martin began his career as an Investment Manager at Bayern Kapital, focusing on seed investments of biotech companies.
Martin holds a PhD in Biology as well as a Master degree in Biology and Economics. He serves on the board of AMP Therapeutics GmbH and ArmaGen Technologies, Inc.
InvestorBessemer Venture Partners
Vinay Iyengar is an investor based in Bessemer Venture Partners' NYC office focused on machine intelligence, cyber security, and vertical SaaS.
He got his start in venture capital at Clayton Christensen's Rose Park Advisors, leading the firm's exploration of machine intelligence as an enabler of disruption. Previously, he spent time at Goldman Sachs and Intel and founded a Harvard Innovation Lab-backed enterprise software startup. He also has conducted extensive cryptography research leading to two peer-reviewed publications.
When not nerding out about technology and startups, Vinay enjoys trying new foods, listening to hip-hop, and cheering on his hometown Portland Trail Blazers. He studied computer science and economics at Harvard.
Founding PartnerUnshackled Ventures
I am passionate about building practical solutions that have a big impact on people's lives. Our personal experiences and those of hundreds of startup teams with founders on visas was the inspiration behind the framework for Unshackled.
An immigrant on visa pursuing my American dream, I am excited about the opportunity to help all entrepreneurs, whether born in the US or elsewhere, to start and grow companies in the US, the mecca of entrepreneurship. I look forward to the opportunity to work with the brightest entrepreneurs solving massive problems!
My particular areas of interest when working with early stage startups are story-telling, pitching, fundraising, product strategy, and bringing in the first customers/sales.
Investment PrincipalMotorola Solutions Venture Capital
Gopal Rajaraman is an Investment Principal with Motorola Solutions Venture Capital. In this role, Gopal identifies, executes, and manages strategic minority private equity investments for Motorola Solutions.
Prior to joining the Motorola Ventures team, Gopal spent fifteen years working within Motorola's Engineering teams in various roles from Software Developer to Lead Architect to Program Owner/Manager, managing several global teams and projects.
Gopal holds an MBA from the University of Chicago Booth School of Business with a concentration in Analytical Finance and Accounting. He also holds a Master of Science degree in Engineering from Purdue University and a B.Tech degree from the Indian Institute of Technology, Madras.
Vice PresidentHIG Capital
Jorge Ramirez is a Vice President at H.I.G. BioHealth Partners, the life sciences investment affiliate of H.I.G. Capital, and focuses on development stage and growth investments in the healthcare sector.
Previously, Jorge was with ProQuest Investments, a healthcare focused private equity firm. During his eight years with ProQuest, the firm raised and fully invested two funds totaling $625 million. He represented ProQuest as an observer or board member in several successful companies including: Eagle Pharmaceuticals (NASDAQ: EGRX); Mevion Medical Systems; Revision Optics; and Mirati Pharmaceutics: (NASDAQ: MRTX).
Jorge earned degrees in Neuroscience and Spanish literature from Amherst College, where he graduated magna cum laude. He earned an M.B.A. from Harvard Business School.
Founder & Managing DirectorWAVE Equity Partners
Praveen Sahay is a co-founder and Managing Director of WAVE Equity Partners, a private equity firm in Boston that provides expansion capital to clean energy, food and water companies at their inflection points of growth.
Originally a Nuclear Physicist, he prospected for offshore oil and gas deposits; managed retail operations for India's largest mutual fund; and led armed battalions as a Deputy Commandant in India. He also helped Mozambique's democratic transition in 1994 as the United Nations Elections Coordinator. Before founding WAVE, he made venture investments at venture funds VIMAC and Updata Venture Partners for 12 years.
Praveen has an MBA from the University of Chicago, a VC Kauffman Fellowship, a degree in Geophysics from IIT Roorkee, an MS in Nuclear Physics, and BS in Physics Honors from St. Stephen's College in New Delhi. He was awarded a UN Peace Medal for his services in Mozambique.
InvestorNew Enterprise Associates
Andrew is a Principal at NEA and is on the founding team of the firms' NYC office, where he focuses on enterprise and consumer technology investments.
Andrew is a Board Director of CCP Games, Qadium, and IONQ, and he is actively involved in NEA's investments in Code42, Curalate, Duolingo, Pocket, ThreatQuotient, and TrackMaven. Prior to NEA, Andrew was an Analyst at Blackstone in New York. In addition, Andrew co-founded Flicstart, a digital media company that was acquired in 2015.
Andrew received his MS as a Schwarzman Scholar at Tsinghua University in Beijing. He received his BA from Cornell University where he graduated with Phi Beta Kappa honors and studied Economics in the College of Arts and Sciences and Science of Earth Systems in the College of Engineering.
Andrew serves on the Advisory Council for Entrepreneurship at Cornell, is President Emeritus of the Cornell Venture Capital Club, and is a Board Member of the National Udall Scholarship Association focusing on issues related to environmental sustainability.
Founder and Managing PartnerGlasswing Ventures
Rudina Seseri is Founder and Managing Partner of Glasswing Ventures.
With over 15 years of investing and transactional experience, Rudina has led technology investments and acquisitions in startup companies in the fields of robotics, Internet of Things (IoT), SaaS marketing technologies and digital media. Rudina's portfolio investments include Talla, Celtra, CrowdTwist, Jibo and SocialFlow.
She graduated magna cum laude from Wellesley College with a BA in Economics and International Relations and with an MBA from the Harvard Business School (HBS).
Vice PresidentNew Energy Capital Partners
Jeph Shaw, Principal at New Energy Capital, focuses on transaction origination, execution and monitoring. Jeph originally joined NEC as an Associate in 2010 and left in 2013 to pursue an MBA.
After business school, Jeph joined SunEdison, where he focused on corporate finance and treasury in the TerraForm Power and TerraForm Global “YieldCo” affiliates before returning to NEC in 2016. Earlier in his career, Jeph was an investment banking analyst focused on M&A advisory with TM Capital.
Jeph is a graduate of Tufts University (BA) and the Tuck School of Business at Dartmouth (MBA).
Managing DirectorGE Ventures
Abhishek works with Nexus, leading US-India VC firm, managing $1.2B across funds.
He is passionate about working with mission-driven founders who are aiming to build transformational companies in technology and healthcare.
Abhishek works closely with Nexus partner companies: Clover, Imagen Technologies, Cricket Health, ZenProspect, HeadOut, and Mezi.
North American Venture ManagerShell Technology Ventures
Carl Stjernfeldt is a Senior Lecturer at the MIT Sloan School of Management.
Carl is a member of the team at Shell Technology Ventures (STV), Shell' s corporate Venture Capital fund. Carl serves as Manager of North American Venture at Shell Technology Ventures since September 2013. STV invests in technology companies focused on the oil & gas and future energy (clean/green tech) markets, as well as IT and mobile technologies that support them. STV acts as a strategic partner and makes minority investments in select technology companies, including Shell technology spin-outs, and also acts as an LP in some externally managed venture capital funds.
Carl has 20 years' experience in managing critical business issues, mainly for high growth technology companies. Carl has served on numerous boards of successful companies including: Agito Networks (acquired by ShoreTel), Arbor Networks (acquired by Tektronix), BNI Video (acquired by Cisco), Broadbus Technologies (acquired by Motorola), Cedar Point Communications (acquired by Genband) and Tejas Networks.
PartnerMVM Life Science Partners
Neil joined MVM in 2015. Prior to joining MVM, he was at Locust Walk Partners, executing a variety of buy- and sell-side transactions across a wide range of company types and therapeutic areas within healthcare. He was also a member of CVS Caremark's strategic development team and a consultant at Oliver Wyman.
Neil began his career at a Howard Hughes Medical Institute lab at the Wadsworth Center in Albany, NY, where he used 3D Cryo-Electron Microscopy techniques to study ribosome structures.
Neil holds an MBA in Healthcare Management from the Wharton School, University of Pennsylvania, and received his A.B. in the History of Science from Princeton University.
Managing DirectorUniversity Ventures
Troy Williams is a Managing Director of University Ventures.
Prior to University Ventures, Troy was a senior executive at Macmillan where he was CEO of Macmillan Enterprise Solutions and President of Macmillan New Ventures, managing an edtech portfolio of seven companies with a focus on data and analytics, university systems and student performance and outcomes.
Troy founded and for nine years was CEO of Questia Media, an early ebook company ultimately sold to Cengage Learning.
Troy received his bachelor's degree in History, Phi Beta Kappa, from Rice University, and his law degree from the Harvard Law School where he was a member of Harvard Law Review.
Troy started his career in the mergers and acquisitions practice at Cravath, Swaine & Moore. He is on the Advisory Board of Rice University's School of Humanities. Troy focuses on investments in software and systems for universities.
Managing DirectorSandbox Industries
Chris is a Managing Director at Sandbox Industries.
He serves as a Board Member of Aspire Health and Picwell. He also helps manage the Fund 's investments in Allay, Benestream, EveryMove and Phreesia.
Chris brings extensive negotiation and deal structure experience from his time in the real estate industry. Additionally, he gained deep operating experience while serving as the CFO of a private equity backed, technology-first consumer packaged goods company.
Chris earned an MBA from the Stanford Graduate School of Business and a BS in Finance from Arizona State University.